Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:26:34.671Z.
Calculation as of: 2026-10-06T21:26:34.671Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
PE RATIO
N/A
Market Cap
$634.30M
PE Ratio
11.53
TTM Avg
10.12
3Y Avg
10.12
5Y Avg
40.88
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $656.59M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 115.50 | 37.43 | 206.22 | 206.22 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 11.53 | 10.12 | 10.12 | 40.88 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$12.56
Forward EPS (Est.)
$-4.14
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
